Subsequent Event
|
3 Months Ended |
---|---|
Mar. 31, 2015
|
|
Subsequent Events [Abstract] | |
Subsequent Event | Subsequent Event In May 2015, the Company acquired financial rights to potential future milestones and royalties for more than 15 biologic development programs from Selexis SA for $4.0 million. Each acquired program is fully funded by a development partner. Selexis is a privately held global life science company based in Switzerland that focuses on drug discovery for lead identification and cell line development of scale-up and manufacturing of therapeutic protein drugs. |